Almac’s North Carolina Facility Continues Growth in Academically based Clinical Trials

06-May-2010 - USA

Almac Clinical services, has seen a continued growth from clients operating in the not- for-profit sector on academically based clinical trials. The site in Durham which recently doubled capacity and passed an FDA inspection, also operates as a licensed pharmacy. The unit was originally part of the Duke Clinical Research Institute from 1990-2000 with all of the studies handled during this time were physician-led and academically based.

Donna Christopher, VP of Operations at Almac Clinical Services, Durham Facility commented ‘As our business continues to evolve under the Almac brand we have stayed close to our roots in academically based clinical trials - an area where our expertise lies. Alongside our core contract services, we also advise many of our clients on how to conduct their trials. From the outset we provide information on clinical input, study materials required, efficient drug kits design as well as full supply chain management in addition to providing training and monitoring to sites. We work together with our Academic clients to ensure their clinical trials are run to maximum efficiency enabling them to focus solely on their trial results. In recent months we have doubled our capacity to enable us to meet the increased demands for our services.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Strand Genomics and MediBIC form business partnership - bioinformatics and data mining solutions in Japan

Hidden RNA repair mechanism discovered in humans - Function of a previously uncharacterized human protein elucidated

Hidden RNA repair mechanism discovered in humans - Function of a previously uncharacterized human protein elucidated

Experience leads to the growth of new brain cells - A new study examines how individuality develops

Experience leads to the growth of new brain cells - A new study examines how individuality develops

Enzo rejects Roche settlement offer - Roche responds with lawsuit

Cold Spring Biotech Corp. to Distribute Strand Genomics' avadis in Taiwan

Syngenta files suit to enforce biotechnology patents

MediGene Receives New US Patent for Cancer-Killing Viruses - Patent protects herpes simplex viruses (HSV) genetically modified to activate the immune system against tumor cells

YM Bioscience reports Phase II data for nimotuzumab in metastatic colorectal cancer - Overall Survival And Disease Control Outcomes, Coupled With Low Toxicity, Support The Continued Development Of The EGFR Antibody In Patients With Colorectal Cancer

SYGNIS completes acquisition of TGR Biosciences

Chemist developed a green catalyst for pharmaceutical and industrial chemistry - Catalyst based on a substance that comes from plant waste

Chemist developed a green catalyst for pharmaceutical and industrial chemistry - Catalyst based on a substance that comes from plant waste

Microbix to spin off Urokinase into newly formed Klarogen Biotherapeutics - Klarogen to acquire all remaining Urokinase inventory, sales and marketing infrastructure and NDA from ImaRx upon completion of financing

Celera Genomics Presents Preclinical Data on its Human Histone Deacetylase (HDAC) Inhibitor